Altogen Labs extensive biotechnology and pharmacology research services include the following:
- PRE-CLINICAL RESEARCH SERVICES
- Pharmacology and toxicology testing: IC50 for Tumor Cell Lines
- Xenograft Animal Service: Immunocompromised NOD/SCID Mice
- Therapeutic RNAi development: targeted siRNA, qPCR assays
- Liposome Encapsulation services: siRNA, miRNA, DNA, proteins
- ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
- Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
- RNAi Consulting Services: technology delevopment & evaluation
- GENERATION OF STABLE CELL LINES
- CELL BANKING
- RNA INTERFERENCE (RNAi) SERVICES
- In vivo siRNA delivery and tissue-targeting
- siRNA Transfection and RNAi Cell-based Library Screening
- Generation of Tet-inducible RNAi gene knockdown cell lines
- RNAi screen pathway analysis: siRNA and microRNA library
- RNAi manufacturing and CRO services
- PCR Cloning: shRNA-encoding vector construction
- In Vivo Stable siRNA and microRNA - Chemical modification
- Quantitation sh/siRNA-induced knockdown by qRT-PCR and WB
- Reporter gene assays and Stable RNAi cell line development
- Genome-wide siRNA and microRNA high-throughput screens
- Stable RNAi Cell Line Generation: Stable Gene Knockdown
- siRNA liposome encapsulation service
- Transient (siRNA) and stable (shRNA) transfection services
- BIOLOGY LABORATORY CRO SERVICES
- BIOREMEDIATION
- BACTERIA ID 16S SEQUENCING
Xenograft Animal Service: Immunocompromised NOD/SCID Mice
Tumors are established in a group of 6- to 7-week-old female BALB/c athymic (nude) mice (or 9- to 11-week-old NOD/SCID immunocompromised mice) by subcutaneous injection of tumor cell line cells (typically 1,000,000 cells per animal). The client selects a cell line of interest (must be tumorigenic) and assigns a number of experimental groups and the size of each Group. The dosing of compounds is initiated when the mean tumor size reaches 50-100 mm3. The client is expected to provide Dose-Group assignment instructions for each Group.
Administration options include the dosing route (intratumoral, intramuscular, oral, intravenous, intratracheal, subcutaneous, and intraperitoneal), dosing frequency (for example, once or twice a day), and dosing duration. If the customer elects to include the cyclophosphamide positive control group, cyclophosphamide (50 mg/kg) will be administered by i.m. injection daily for the duration of the study.
Analysis is performed daily with cage-side observations. Body weight and tumor volume are estimated every other day; tumor volume (mm3) is calculated using "(W x W x L) / 2" formula, where W is tumor width and L is length.
Altogen Labs offers multiple xenograft tumor models, including A549, DU-145, PC-3, U87MG, MDA-MB, PANC1, Caki-1, Caki-2, SKMEL, A431, LnCAP, FaDu, HeLa, SKOV-3, SW-480, and many other cell lines. Following acclimatization, mice are grouped according to body weight. Human cancer cell lines are prepared in Matrigel and grafted subcutaneously into the flank area. Mice are checked daily for clinical signs and tumor appearance.
Once tumors begin to appear, animals are grouped based on tumor volume. Mice are dosed once or twice per day for 28 days via one route of administration (choice of oral, intratumoral, intraperitoneal, intratracheal, intramuscular, or subcutaneous). Tumor volume and body weight are measured once per week.
Blood sera can be collected at termination, and tumors and other major tissues can be collected and preserved if required.
Once we know the details of your project, we can provide you an immediate price quote (contact e-mail: info@altogenlabs.com). Please note that experimental details will help us to provide an accurate quote and timeline estimate.
see also: Pharmacology and toxicology testing: IC50 for Tumor Cell Lines | Xenograft Animal Service: Immunocompromised NOD/SCID Mice | Therapeutic RNAi development: targeted siRNA, qPCR assays | Liposome Encapsulation services: siRNA, miRNA, DNA, proteins | ELISA and Cell-Based Assay Development (Cell Cycle, Viability) | Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen | RNAi Consulting Services: technology delevopment & evaluation